1月27日，A股延续震荡，硬科技彰显韧性，科创芯片ETF华宝（589190）下探回升，场内价格一度涨近2%，现涨1.71%，东芯股份20CM涨停，芯源微涨超 13%。 | A | | 多日 1分 5分 15分 30分 | | 60分 = | | | F9 盘前盘后 叠加 九转 画线 工具 @ 2 | | | N科创成 | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 589190[N科创芯片E . 华宝] 10:36 价 1.010 涨跌 0.017(1.71%) 均价 1.000 成交量 | | | | | | | | 1011 | | | | | | | | | 1.76% | TEOT | | | 1.002 | | | | | | | | | 0.88% | SSE CNY 10:36:16 | 交易中 | | 0.993 | | | | | | | | | 0.00% | 净信数字 | 45 | | 0.984 | | | | | | | | | 0.88% | 委比 ...

Core Viewpoint - The control of Mengniu over Miaokelando (600882) appears to be entering a new phase following the dismissal of founder Chai Xiu from key positions, with Kuai Yulong appointed as the new general manager [1][10]. Management Changes - Chai Xiu has been removed from the positions of vice chairman, general manager, and legal representative as of January 23, while still retaining his role as a director [1][3]. - Kuai Yulong, who has a strong background with Mengniu, has been appointed as the new general manager, with the legal representative role also changing to him [1][3]. Financial Impact - The dismissal of Chai Xiu is linked to a historical investment guarantee dispute that has negatively impacted Miaokelando's performance, leading to significant asset impairment losses estimated to reduce net profit by approximately 119 million to 127 million yuan [4]. - The company reported a revenue increase of 14.22% year-on-year to 1.39 billion yuan for Q3 2025, with net profit rising by 214.67% to 42.97 million yuan [7]. Market Dynamics - The growth is attributed to the B-end market, particularly in the mozzarella cheese sector, where domestic products are replacing imports [8]. - Mengniu's extensive upstream resources are providing stability in raw milk supply and cost, enhancing the competitiveness of domestic cheese products [8][9]. Stock Performance - Following the management changes, Miaokelando's stock price fell by over 2%, with a current market capitalization of 11.6 billion yuan [11].

Core Viewpoint - The control of Mengniu over Miaokelando may be entering a new phase following the dismissal of founder Chai Xiu from key executive positions, with Kuai Yulong appointed as the new general manager [1][12][21] Group 1: Management Changes - Chai Xiu has been removed from the positions of vice chairman, general manager, and legal representative but will remain a board member [1][12] - Kuai Yulong, who has a strong background with Mengniu, has been appointed as the new general manager [1][12][19] - Mengniu currently holds over 37% of Miaokelando's shares, indicating significant control [12][19] Group 2: Financial Impact - A guarantee dispute related to an investment has led to substantial financial implications for Miaokelando, with expected asset impairment losses reducing net profit by approximately 119 million to 127 million yuan [4][15] - Miaokelando's revenue for Q3 2025 increased by 14.22% to 1.39 billion yuan, while net profit surged by 214.67% to 42.97 million yuan [6][18] - The company's recovery is attributed to the B-end market, particularly in the mozzarella cheese sector, benefiting from Mengniu's resources [19][20] Group 3: Market Reaction - Following the management changes, Miaokelando's stock price fell by over 2%, with a current market capitalization of 11.6 billion yuan [8][22]

作者 丨贺泓源 实习生徐鸿儒 编辑丨高梦阳 蒙牛对妙可蓝多的控制或步入新阶段。 1月25日， 总部位于上海的 妙可蓝多公告，柴琇被免副董事长、总经理及法定代表人职务，但继续担任公司董事。同时，公司聘任蒯玉龙为总 经理，法定代表人相应变更为蒯玉龙，其不再兼任公司行政总经理。 61岁的柴琇为妙可蓝多创始人。 | | | | | | 是否继续在 | 날 体 | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任 | 离任 | 原定任期 | 离任 | 上市公司 | | 未履行完毕的 | | | 职务 | 时间 | 到期日 | 原因 | 及其控股子公司 | 职 | 公开承诺 | | | | | | | 任职 | 务 | | | 柴珍 | 副重事 长、总经 理以及 | 2026 年 1月23日 | 2027 年 11月17日 | 免职 | 是 | ロ 書 | 是 | | | 法定代 | | | | | | | | | 表人 | | | | | | | | | 行政总 | 2026 年 | | 工作 | | 直 事 1 | | | | | | ...

Group 1 - The A-share market continues to show resilience in hard technology, with the Huabao Sci-Tech Chip ETF (589190) experiencing a price increase of nearly 2% at one point, currently up 1.71% [1] - Dongxin Co., Ltd. has reached a 20% limit up, while Chip Source Microelectronics has risen over 13% [1] - The Huabao Sci-Tech Chip ETF passively tracks the Shanghai Stock Exchange Sci-Tech Chip Index, which has a significant focus on the chip industry, covering nearly 80% in core areas such as chip design and semiconductor materials and equipment [3][5] Group 2 - Samsung Electronics has raised the supply price of NAND flash memory by over 100% in the first quarter, exceeding market expectations, and is expected to continue price negotiations for the second quarter [3] - CITIC Securities is optimistic about investment opportunities in semiconductor chips, driven by advanced processes and domestic substitution, recommending attention to leading companies with platform capabilities and high-elasticity niche leaders [3] - The Shanghai Stock Exchange Sci-Tech Chip Index has shown annualized returns of 17.93% since its base date, significantly outperforming similar indices [3][5]

Market Overview - The market experienced a mild increase this week, with the average daily trading volume in the Shanghai and Shenzhen markets significantly declining, yet remaining at a historical high of approximately 2.7 trillion [1][3] - A-shares have escaped short-term emotional fluctuations and returned to a rational operational track, supporting a steady and gradual bull market trend [1][3] - Market activity remains high, indicating numerous investment opportunities [1][3] Investment Strategy - The company anticipates that the market will exhibit a "slow bull" characteristic until the Chinese New Year, with rapid theme rotations [1][3] - A long-term investment strategy is recommended, focusing on selecting stocks with favorable long-term trends while avoiding short-term speculation [1][3] Long-term Focus Areas 1. The repeated TACO (Trade Adjustment and Cooperation Agreement) by the U.S. may lead countries to accelerate self-sufficiency in defense, resources, finance, and supply chains, intensifying resource competition and indicating an upward cycle for commodities [1][3] 2. The intensifying global technology competition is driving the domestic strategy for technological self-reliance, presenting dual development opportunities in the A-share technology growth sector through domestic substitution and industrial upgrading [1][3] Industry Performance - In the past week, the construction materials, oil and petrochemicals, and steel industries performed notably well, with respective increases of +9.23%, +7.71%, and +7.31% [14]

21世纪经济报道记者贺泓源、实习生徐鸿儒 蒙牛对妙可蓝多（600882）的控制或步入新阶段。 1月25日，妙可蓝多公告，柴琇被免副董事长、总经理及法定代表人职务，但继续担任公司董事。同 时，公司聘任蒯玉龙为总经理，法定代表人相应变更为蒯玉龙，其不再兼任公司行政总经理。柴琇为妙 可蓝多创始人。 蒯玉龙则有着浓郁的蒙牛背景。他于2021年随蒙牛入股担任妙可蓝多任财务总监，2025年升任行政总经 理。作为控股股东，蒙牛目前持股超37%。截至2025年末，柴琇依旧为妙可蓝多第二大股东，算上一致 行动人吉林省东秀商贸总计持股15.96%。 需要注意的，基于柴琇被免职，其与蒙牛关系显得有些尴尬。 另据21世纪经济报道记者了解，柴琇对妙可蓝多的种种经营策略，在内部也遭遇了越来越多争议。 眼下，妙可蓝多终于回归增长区间。 2025年三季度，该公司营收同比增长14.22%至13.90亿元；归母净利润同比增长214.67%至4297万元。 背后是B端市场推动，尤其是在马苏里拉奶酪市场实现国产替代。 对此，有头部乳业高管向21世纪经济报道记者解释，蒙牛更庞大的上游牧场资源，对妙可蓝多稳定原奶 规模与成本起到很大帮助。尤其现在的奶价 ...

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. is expected to achieve a net profit of approximately 1.242 billion yuan for the year 2025, marking a significant turnaround in performance and entering a new phase of high-quality development [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 1.242 billion yuan and a net profit of about 402 million yuan after deducting non-recurring gains and losses, both indicators showing a year-on-year turnaround [1] - The strong recovery in performance is attributed to product iteration, market expansion, R&D innovation, and improved corporate governance [1] Group 2: Market Dynamics - The domestic insulin market has undergone two rounds of procurement reshuffling, leading to an increase in domestic market share and an optimized competitive landscape [1] - Tonghua Dongbao's third-generation insulin sales have increased by over 100% year-on-year, contributing significantly to revenue and shifting the product structure towards a balanced development of both second and third-generation insulins [2] - The company holds a market share of 45.5% in second-generation insulin, maintaining its leadership position in the domestic market [2] Group 3: International Expansion - The company has seen a nearly 80% year-on-year growth in overseas revenue, with international business becoming a crucial growth driver [3] - Key international registrations include the acceptance of the aspart insulin BLA by the FDA, marking a significant step into high-end markets [3] - The company has successfully registered various insulin products in multiple countries, enhancing its international competitiveness [3] Group 4: R&D Innovation - Tonghua Dongbao has increased its R&D efforts, achieving significant progress in several core projects, including the completion of Phase III clinical trials for semaglutide [4] - The company is advancing its pipeline in metabolic disease treatments, with promising results in clinical trials for various products [4] Group 5: Corporate Governance - The company has launched an employee stock ownership plan to align the interests of shareholders, the company, and key employees, enhancing team cohesion and core competitiveness [5] - The controlling shareholder has increased its stake by 228 million yuan, reflecting confidence in the company's future [5] - The company plans to repurchase shares worth 20 to 40 million yuan to support the employee stock ownership plan, stabilizing market expectations [5] Group 6: Future Outlook - Looking ahead, the company aims to solidify its domestic insulin market position, optimize product structure, and expand market share [6] - The company will accelerate its international strategy and enhance its global value chain capabilities [6] - Continued focus on innovation and expanding its product portfolio in metabolic disease treatment is expected to showcase the company's resilience and industry leadership [7]

Core Viewpoint - The company expects significant growth in sales revenue from PCB specialized processing equipment and various spindle products by 2025, driven by increased demand in the PCB market due to AI computing infrastructure and consumer electronics upgrades, as well as accelerated domestic substitution and technological innovation [1] Group 1: Financial Performance - The company anticipates a substantial increase in net profit attributable to shareholders in 2025, supported by improved gross margins from scale effects [1] Group 2: Operational Strategy - To address the significant rise in order volume and ensure delivery capability for future growth, the company has proactively initiated capacity planning and resource allocation [1] - The company is also planning to establish dedicated production lines related to PCB to enhance delivery assurance and reserve capacity for future business development [1] - Currently, the company's overall production organization and delivery pace are operating smoothly, with related orders being delivered steadily as planned [1]

Core Insights - The "14th Five-Year Plan" emphasizes extraordinary measures to achieve decisive breakthroughs in key core technologies across various sectors, including integrated circuits and artificial intelligence [1][2] - The launch of the Huabao Science and Technology Chip ETF (589190) aims to provide investors with opportunities to engage in the domestic chip industry, tracking the Shanghai Stock Exchange Science and Technology Chip Index [1][2] Industry Overview - The chip industry is a core battleground for major countries, with the Huabao Science and Technology Chip ETF tracking an index that includes 50 companies involved in semiconductor materials, design, manufacturing, packaging, and testing [2][14] - As of December 2025, the index's components focus on upstream and midstream sectors, with nearly 80% in chip design and semiconductor materials and equipment [2][15] Performance Metrics - The Shanghai Stock Exchange Science and Technology Chip Index has shown a significant annualized return of 17.93% from December 31, 2019, to December 31, 2025, outperforming similar indices [5][17] - The index's maximum drawdown during the same period was -56.81%, which is better than other comparable indices [5][17] Key Holdings - The top three holdings in the index are SMIC (10.36%), Haiguang Information (10.05%), and Cambricon (9.45%), with a weight limit of 10% for individual stocks [3][16] - The index includes a diverse range of companies, with a significant focus on integrated circuit manufacturing [3][16] Financial Highlights - The net profit of the index's constituent companies surged by 94.22% in the first three quarters of 2025, leading among similar indices [7][17] - R&D investment for these companies reached 119.745 billion yuan, with a research intensity of 11.22%, significantly higher than the overall A-share market [7][17] Fund Management - As of January 26, 2026, Huabao Fund's equity ETF assets reached 139.8 billion yuan, ranking 9th in the industry [19] - The fund has established a comprehensive ETF matrix covering AI and technology sectors, with the Science and Technology Chip ETF being a crucial addition [19]